Science and Enterprise

Month: September 2010

  • Genomic Map Developed for Domesticated Turkey

    Researchers from the U.S. Department of Agriculture (USDA) and colleagues from universities, research institutes, industry, and other agencies have sequenced the majority of the genome of Meleagris gallopavo, the domesticated turkey, creating the first-ever turkey genome map. The nearly complete map could help growers to more efficiently produce bigger, meatier turkeys. The research is reported…

  • European Patent Awarded for Herpes Treatment

    BioAlliance Pharma SA in Paris, France say it has been granted a European patent protecting its product acyclovir Lauriad. This patent, says the company, specifically protects the muco-adhesive tablet containing acyclovir, its process for manufacturing, and its clinical application. According to BioAlliance Pharma, acyclovir Lauriad provides treatment of recurrent herpes labialis with one tablet application…

  • Funding Announced for Carbon Capture and Storage R&D Projects

    The U.S. Department of Energy announced the selection of 22 research and development projects on carbon capture and storage (CCS) for industrial sources. Funded with more than $575 million from the American Recovery and Reinvestment Act, these “clean coal” R&D projects follow on earlier industrial demonstration projects also funded through the Recovery Act. Some $312…

  • BP Offers $10 Million to NIH for Gulf Health Research

    The oil producer BP said today it is providing $10 million to the National Institutes of Health (NIH) under its Gulf of Mexico Research Initiative (GRI) to support a study of potential public health issues relating to the Gulf oil spill and other spill-related health research. The GRI is a 10-year, $500 million independent research…

  • Phase 2 Clinical Trial Planned for Depression Drug

    Rexahn Pharmaceuticals Inc., a clinical stage pharmaceutical company in Rockville, Maryland, submitted today a Phase 2b protocol to the U.S. Food and Drug Administration for the clinical study of Serdaxin, a drug that treats major depressive disorder. The company says Serdaxin may work as an enhancer of serotonin and dopamine in the brain. In Rexahn’s…

  • Forensic Science Center Creates For-Profit Company

    The National Forensic Science Technology Center (NFSTC) in Largo, Florida has created the Forensic Innovation Center, a new, for-profit enterprise also in Largo. NFSTC conducts forensic research, education programs, and laboratory quality reviews, and evaluates forensic technologies. The Forensic Innovation Center (FIC) will conduct its work under contracts, separate from the grants and cooperative agreements…

  • Drug Companies Urged to Conserve Antibiotics to Fight Resistance

    A new report recommends that pharmaceutical companies take a different approach to combating resistance to antibiotic drugs. An article published today in the journal Health Affairs suggests physicians, hospitals, and drug makers coordinate their practices to extend the effective lifetimes of antibiotics. The paper, by Aaron S. Kesselheim of Brigham and Women’s Hospital and Harvard…

  • Computer-Vision System Unveiled for Auto Collision Avoidance

    Mobileye N.V., a developer of vision-based collision prevention systems in Amsterdam, The Netherlands, released its Mobileye C2-270 system featuring the EyeQ2 vision chip that detects pedestrians, vehicles, bicycles, and lane markings. The company says this device can saves lives by alerting and prompting drivers in the critical seconds before a collision occurs. The company says…

  • Chinese Patents, R&D Funds Climb in 2010

    The Xinhua news agency reports that the number of patents and research and development funding by China’s largest companies have climbed so far in 2010, according to data released by the China Enterprise Confederation (CEC). The CEC says China’s top 500 companies held 169,000 patents in 2010, up 13.3 percent from last year. Some 41…

  • Light reporting on Monday

    ( SU7AJNCPJXKQ ) Monday, 6 September, is the Labor Day holiday in the U.S., and with the markets and most businesses closed, there will likely be little news to report. But we will keep our eyes open for any developments outside the U.S. worth reporting.